# LabCorp

> LabCorp is a VC fund in Burlington backing Health Care and Biotechnology. See 56 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Burlington, United States
- Total investments: 56
- Last investment: Dec 2025
- Lead investor: 18%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/labcorp/
- X (Twitter): https://twitter.com/labcorp
- Website: https://www.labcorp.com/
- Facebook: https://www.facebook.com/LabCorp-1639041059681535/

LabCorp is a VC fund in Burlington focused on Health Care and Biotechnology. Labcorp specializes in providing physicians with laboratory tests. They develop new tests that provide enhanced accuracy and additional clinical information. Their customers include physicians and their patients, hospitals and managed care plans, private employers, military and law enforcement agencies, and pharmaceutical and biotechnologycompanies.

## Contacts

5 contacts available for LabCorp. Shizune tracks 10 team members at LabCorp. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/laboratory-corporation-of-america?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 34 | 61% |
| Biotechnology | 24 | 43% |
| Health Diagnostics | 20 | 36% |
| Medical | 15 | 27% |
| Software | 8 | 14% |

41 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 17 | 30% |
| Series A | 16 | 29% |
| Series C | 7 | 13% |
| Funding Round | 5 | 9% |
| Seed | 3 | 5% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 39 | 70% |
| Canada | 2 | 4% |
| United Kingdom | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Steven Anderson | Global Head of Clinical Trials | 1 | https://shizune.co/investors/profile/steven-anderson-5 |
| Amy B. Summy | Executive Vice President & CMO | 1 | https://shizune.co/investors/profile/amy-b-summy |
| Araceli Reyes | Divisional Medical Director, Northeast Division | 0 | https://shizune.co/investors/profile/araceli-reyes |
| Arthur Zebelman | Technical Director | 0 | https://shizune.co/investors/profile/arthur-zebelman |
| Horacio Vall | VP Science and Technology | 0 | https://shizune.co/investors/profile/horacio-vall |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cofactor Genomics | Cofactor Genomics is a company focused on predictive immune modeling. They aim to advance precision medicine by overcoming existing barriers. Cofactor facilitates the shift from single-analyte biomarkers to more comprehensive multidimensional biomarkers using health expression models. Their capabilities include molecular, informatic, and databasetools, with one of the first CAP-certified clinical RNA sequencing laboratories. This certification helps their partners conduct clinical trials more efficiently and cost-effectively. Their expertise in molecular biology, informatics, and database management enables them to provide high-quality services to the healthcare and pharmaceutical sectors, contributing to medical research and improving patient outcomes. |  | Venture - Series Unknown | Dec 15, 2025 |  |
| Mercy BioAnalytics | Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018. | $59M | Series B | Sep 03, 2025 |  |
| GeneCentric Therapeutics | GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina. | $8M | Series C | Jun 18, 2025 |  |
| PreciseDx | PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. | $11.2M | Series B | Jun 05, 2025 |  |
| Outcomes4Me | Outcomes4Me provides an AI-powered digital platform designed to assist cancer patients in managing their care. The platform integrates clinical guidelines, genomic data, and clinical trial information to offer personalized treatment options. Patients can access features such as symptom tracking, medication management, and tailored clinical trialmatching. Outcomes4Me also facilitates the organization and understanding of medical records, enabling users to make informed decisions in collaboration with their healthcare providers. The platform is developed in collaboration with experts in oncology and aims to support patients throughout their treatment journey. | $21M | Series A | May 29, 2025 |  |
| CND Life Sciences | CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $13.5M | Series A | May 01, 2025 |  |
| Olaris | Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline ofmyOLARIS™ precision diagnostics. To learn more, visit https://www.myolaris.com/The company was founded in 2013 and is headquartered in Framingham, Massachusetts. |  | Series B | Apr 08, 2025 |  |
| Percipio Health | Percipio Health uses AI based insights to help clinicians and caregivers maintain holistic view of a patient's health. | $20M | Series A | Jan 21, 2025 |  |
| Teal Health | Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical cancer screenings. We believe that it’s time for women’s health to be designed for women, their preferences, and their experiences. With this in mind, Teal Health is creating the first FDA-approved at-home cervical cancer screening makingit simple for a woman to stay current on this life-saving screening from the comfort, convenience, and privacy of her home. Through timely screenings, Teal health plans to eradicate cervical cancer in the US.Teal is backed by passionate and committed investors who share this important vision, including Felicis Ventures, Emerson Collective, Metrodora, and Serena Ventures. | $10M | Seed | Jan 16, 2025 |  |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M | Series C | Jan 08, 2025 |  |

10 of 56 investments shown.

## Co-investors
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 6 deals together
- [Bruker](https://shizune.co/investors/profile/bruker) — VC Fund, 4 deals together
- [Merck Global Health Innovation Fund](https://shizune.co/investors/profile/merck-global-health-innovation-fund) — VC Fund, 4 deals together
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together
- [Arsenal Capital Partners](https://shizune.co/investors/profile/arsenal-capital-partners) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does LabCorp invest in?

LabCorp invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series B and Series A stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact LabCorp?

Public channels for LabCorp include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LabCorp?

The team at LabCorp includes Steven Anderson (Global Head of Clinical Trials), Amy B. Summy (Executive Vice President & CMO) and Araceli Reyes (Divisional Medical Director, Northeast Division), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co